ICH S7A gives every nonclinical program the same fixed starting point: a core battery covering the central nervous, cardiovascular, and respiratory systems, run before a new chemical entity or biotechnology-derived pharmaceutical reaches first-in-human dosing. Regulators treat that core battery as close to non-negotiable. What comes after it is not fixed at all — S7A hands the sponsor a judgment call on follow-up and supplemental studies, built on illustrative triggers rather than a checklist, and the written rationale behind that call is exactly what an IND or CTA reviewer tests.

What the core battery actually requires

The core battery assesses three vital organ systems before human exposure: the central nervous system (motor activity, behavioral changes, coordination, sensory/motor reflex responses, body temperature), the cardiovascular system (blood pressure, heart rate, and the electrocardiogram), and the respiratory system (respiratory rate and depth, together with a measure of oxygenation). FDA and the other ICH regulators expect this battery complete, generally under GLP, before dosing starts in an IND-enabling program — a timing requirement that sits alongside, not instead of, ICH M3(R2)'s broader nonclinical-to-clinical timing framework. The cardiovascular strand has its own companion guideline: in vitro and ex vivo repolarization assessment is addressed separately under ICH S7B, and where an integrated nonclinical-to-clinical QT strategy applies, that work coordinates with the clinical thorough-QT replacement approach under ICH E14/S7B.

3 systems
CNS, cardiovascular, and respiratory — the fixed core battery before first-in-human dosing.
Nov. 2000
ICH S7A's Step 4 adoption date — one of ICH's oldest unrevised safety guidelines.
Illustrative, not exhaustive
How S7A itself frames the follow-up-study trigger list — the sponsor still has to make the call.

The follow-up decision is where programs get it wrong

S7A names several circumstances that can call for follow-up or supplemental studies: a signal arising from the core battery itself, the compound's known pharmacological or chemical class, findings elsewhere in the nonclinical package, or clinical and pharmacovigilance experience with related compounds. The guideline is explicit that these examples are illustrative rather than exhaustive — it does not hand a sponsor a closed list to check off. Teams that treat the core battery as the entire safety pharmacology obligation, and skip the documented screen for follow-up triggers, are the ones who get the deficiency letter asking why a known class effect was not investigated further. Teams that run the screen and find nothing actionable are not done either — the negative determination needs its own written rationale, because an unrecorded decision not to study something reads, on review, identically to a decision nobody made.

  • Core-battery signal. An equivocal or adverse finding in the CNS, cardiovascular, or respiratory core battery is the most direct trigger for a mechanistic follow-up study.
  • Pharmacological or chemical class. A known class liability — even one not yet observed in your own compound — can justify a supplemental study the core battery alone would not flag.
  • Other nonclinical findings. A signal from a toxicology or pharmacokinetic study outside the core battery itself can still point back to a safety pharmacology question.
  • Clinical or pharmacovigilance experience. Adverse-event patterns in related compounds or earlier-phase trials can trigger a targeted study later in development, not only before first-in-human.
S7A does not ask for a longer battery of tests. It asks for a documented reason, built from the signals in front of you, for whatever you decided to do next. Why the written rationale is the deliverable

A 25-year-old guideline, and an open modernization question

ICH S7A reached Step 4 in November 2000 and has not been substantively revised since — FDA's guidance for industry carries a January 2025 administrative-update date on its guidance page, but the underlying technical content traces to the original 2001 adoption. That durability has drawn scrutiny. A multi-stakeholder collaborative convened by the Health and Environmental Sciences Institute, and a 2025 points-to-consider paper from academic and industry authors, have both proposed modernizing the guideline toward a weight-of-evidence framework that draws on newer in vitro, in silico, and in vivo platforms, potentially merged with ICH S7B into a single modality-agnostic standard. As of this writing, that is a live discussion in the literature and at workshops — not a published ICH concept paper or a confirmed Step 2 work item. Sponsors building a program today should plan against the guideline as it currently stands in nonclinical development strategy, and watch for a formal ICH announcement rather than anticipating one.

Practical readiness sequence
  1. Build the core battery first as the fixed baseline, under GLP, ahead of first-in-human dosing.
  2. Screen for follow-up triggers early — core battery signals, pharmacological class, other nonclinical data, clinical experience — before the timeline forces the call.
  3. Document the no-further-study rationale, not only the studies you did run.
  4. Coordinate the cardiac strand with S7B and E14 so the nonclinical and clinical QT data tell one coherent story.

None of this changes what the core battery costs to run. It changes what a reviewer finds when they open the safety pharmacology section of the submission: either a battery plus a reasoned account of what was screened for and why nothing further was needed, or a battery and silence on everything S7A asked the sponsor to consider. The first version survives review. The second invites the question. Building that rationale alongside the rest of the weight-of-evidence documentation ICH S2(R1) already requires elsewhere in the nonclinical package keeps the program's safety story consistent end to end.

Frequently asked questions

Is the ICH S7A core battery mandatory before first-in-human trials?

ICH S7A does not use the word mandatory, but in practice it is: FDA and other ICH regulators expect the central nervous system, cardiovascular, and respiratory core battery to be complete before first human dosing for new chemical entities and biotechnology-derived pharmaceuticals, absent a documented justification for omitting a component.

What triggers a follow-up or supplemental safety pharmacology study under S7A?

S7A lists illustrative, not exhaustive, triggers: a signal from the core battery itself, the compound's pharmacological or chemical class, findings from other nonclinical studies, or clinical and pharmacovigilance experience with related compounds. The sponsor decides and documents the rationale case by case.

Is ICH S7A being revised?

ICH has not published a concept paper or reached a formal step on an S7A revision as of this writing. Industry groups and a multi-stakeholder HESI collaborative have published points-to-consider papers proposing a modality-agnostic, weight-of-evidence update, often alongside ICH S7B — discussion, not yet a confirmed ICH work item.

Sources & further reading

  1. FDA. S7A Safety Pharmacology Studies for Human Pharmaceuticals — Guidance for Industry (July 2001). fda.gov
  2. ICH S7 Expert Working Group. S7A Step 4 Guideline Presentation (Step 4, November 2000). ich.org
  3. Valentin, J.-P. and Leishman, D. Points to consider for revising the ICH S7A guideline on safety and secondary pharmacology. Regulatory Toxicology and Pharmacology (2025). sciencedirect.com

This article is provided for general informational purposes and reflects the regulatory landscape as of its publication date. It is not legal or regulatory advice. Confirm the current ICH S7A guideline text and any revision status directly with ich.org or FDA before relying on it.